A. Publications

Journal articles


5. Hess PL, Kennedy K, Cowherd M, Virani SS, Masoudi FA, Navar AM, Yeh RW, Ho PM, Maddox TM. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: an NCDR Research to Practice (R2P) project. *Am Heart J* 2018;195:151–152.


76. Saeed A, Virani SS. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. Front Biosci (Landmark Ed) 2018;23:1099–1112.


93. Aronis KN, Zhao D, Hoogeveen RC, Alonso A, Ballantyne CM, Guallar E, Jones SR, Martin SS, Nazarian S, Steffen BT, Virani SS, Michos ED. Associations of lipoprotein(a)


Yechoor VK, Moulik M. Tead1 is required for maintaining adult cardiomyocyte function, and its loss results in lethal dilated cardiomyopathy. JCI Insight 2017;2:93343.


**Books and book chapters**

1. **Bozkurt B.** Epidemiology, pathophysiology and diagnosis of heart failure. In: Fonarow G (ed). *Heart Failure @Point of Care*. Projects in Knowledge Inc

**Presentations (Oral and Poster)**

American Heart Association Scientific Sessions 2017: 50
American College of Cardiology Scientific Session 2018: 38

**B. Awards and honors**

1. **Alam:** Founding Member, Houston Chapter, International Society of Endovascular Specialists
2. **Alam:** Norton Rose Fulbright Faculty Excellence Award, Teaching and Evaluation, Baylor College of Medicine
3. **Alam:** Member, Academy of Distinguished Educators, Baylor College of Medicine
4. **Alam:** Early Career Award for Excellence in Patient Care, Baylor College of Medicine
5. **Alam:** Top Doctors, *Texas Monthly Magazine*
6. **Ballantyne:** Houston Chronicle Top Doctors 2017
7. **Ballantyne:** Castle Connaly Top Doctors: Southeast Texas, Castle Connaly Medical
8. **Ballantyne**: Castle Connaly Top Doctors in Texas for the Speciality of Cardiovascular Disease, Castle Connolly Medical Ltd., 2017
9. **Ballantyne**: Castle Connaly Top Doctors in America, Castle Connolly Medical Ltd., 2018
10. **Ballantyne**: Selected by his peers for inclusion in Best Doctors in America®, Best Doctors, Inc., Aiken, South Carolina, 2018
11. **Ballantyne**: 2017 Highly Cited Researcher presented by Clarivate Analytics, Web of Science, top 1% of researchers most cited
12. **Bozkurt**: Women of Excellence recognition, Baylor College of Medicine, 2018
15. **Denktas**: Star Award for Excellence in Patient Care, Baylor College of Medicine, 2018
16. **Deswal**: Houston Top Doctors, 2017
17. **Diez**: Cigna High Evidence Based Medicine Score and National Committee for Quality Assurance NCQA Physician Recognition, 2017
18. **Diez**: United Healthcare Premium Care Physician, 2017
19. **Hamzeh**: Nasser Lakkis Excellence in Teaching Award, Baylor College of Medicine, 2017
21. **Lakkis**: Excellence in Teaching Award, General Cardiology, 2017
22. **Lakkis**: Excellence in Teaching Award, Interventional Cardiology, 2017
23. **Lakkis**: Top cardiologist in Houston, *Houstonia*, 2018
24. **Levine**: Master Clinician Award, Baylor College of Medicine, 2018
25. **Levine**: Fulbright & Jaworski Faculty Excellence Award – Full Professor, , 2018
26. **Levine**: Visiting Professor, Cleveland Clinic, Cleveland, OH, 2018
27. **Levine**: Visiting Professor, Mt. Sinai Medicinal Center, New York, NY, 2017
28. **Nair**: Star Award for Clinical Excellence, Baylor College of Medicine, 2018
29. **Nair**: That's The Way Award: Promoting Positive Patient Experience, Baylor College of Medicine, 2018
30. **Nazeri**: Fellow, American College of Cardiology
31. **Nazeri**: Fellow, Heart Rhythm Society
32. **Shah**: Norton Rose Fulbright Faculty Excellence Award, Teaching and Evaluation, Baylor College of Medicine
33. **Shah**: Norton Rose Fulbright Faculty Excellence Award, Enduring Educational Materials, Baylor College of Medicine
34. **Shah**: Member, Academy of Distinguished Educators, Baylor College of Medicine
35. **Shah**: Leadership Academy, Cohort III, American College of Cardiology
36. **Shah**: Fellow of American Heart Association
37. **Shah**: Fellow of American Society of Echocardiography
38. **Stainback**: Texas "Super Doctors" 2018
39. **Virani**: Norton Rose Fulbright Faculty Excellence Award, Development of Enduring Educational Materials, Baylor College of Medicine
40. **Virani**: Inducted into Best Doctors database
41. **Wehrens**: Outstanding Investigator Award, International Society for Heart Research

C. Professional organization/association offices held

1. **Alam**: Membership Committee, Society of Cardiac Angiography and Interventions
2. **Arya**: Task Force for Point of Care Ultrasound in Medical Education, American Society of Echocardiography
3. **Ballantyne**: Chair, LDL: Address the Risk Think Tank, American College of Cardiology
4. **Ballantyne**: Writing Committee, Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, American College of Cardiology
5. **Ballantyne**: Board, American Society for Preventive Cardiology
6. **Ballantyne**: Board, National Lipid Association
7. **Ballantyne**: Scientific Meeting Committee, National Lipid Association
8. **Ballantyne**: Co-chair, Project Review Committee, National Lipid Association
9. **Birnbaum**: Board of Directors, International Society of Electrocardiology
10. **Bozkurt**: Member, Question Writing Committee, Advanced Heart Failure and Cardiac Transplant, American Board of Internal Medicine
11. **Bozkurt**: Member, Clinical Policy Approval Committee, American College of Cardiology
12. **Bozkurt**: Member, Health Failure Therapies App Work Group, American College of Cardiology
13. **Bozkurt**: Member, Informatics and Health IT Task Force, American College of Cardiology
14. **Bozkurt**: Member, Subspecialty Work Group, Membership Committee, American College of Cardiology
15. **Bozkurt**: Member, Science and Quality Operations Subcommittee, American College of Cardiology
16. **Bozkurt**: Chair, Heart Failure and Transplant Council, American College of Cardiology
17. **Bozkurt**: Chair, ACCF/AHA Task Force on Clinical Data Standards
18. **Bozkurt**: Member, ACC/AHA HF Guideline Toolkit Work Group
19. **Bozkurt**: Member, ACCF/AHA Task Force on Clinical Practice Guidelines
20. **Bozkurt**: Member, ACCF/AHA Task Force on Performance Metrics
21. **Bozkurt**: Member, Board of Directors, Heart Failure Society of America
22. **Bozkurt**: Treasurer, Heart Failure Society of America
23. **Bozkurt**: Chair, Finance Committee, Heart Failure Society of America
24. **Bozkurt**: Member, Clinical Research Network Committee, Heart Failure Society of America
25. **Bozkurt**: Member, Development Committee, Heart Failure Society of America
26. **Bozkurt**: Member, Membership Committee, Heart Failure Society of America
27. **Bozkurt**: Member, Nominations Committee, Heart Failure Society of America
28. **Bozkurt**: Member, Strategic Planning Subcommittee, Heart Failure Society of America
29. **Denktas**: Member, Competency Management Committee, American College of Cardiology
30. **Denktas**: Member, Anticoagulation Work Group, American College of Cardiology
31. **Denktas**: Member, Exhibits Committee, American College of Cardiology
32. **Denktas**: Member, Education Committee, Society for Cardiovascular Angiography and Interventions
33. **Deswal**: Topic Coordinator, Annual Scientific Session Program Committee (Heart Failure), American College of Cardiology
34. **Deswal**: Member, Annual Scientific Session Program Committee (Heart Failure), American College of Cardiology
35. **Deswal**: Member, Joint American College of Cardiology/American Heart Association Task Force on Clinical Performance Guidelines
36. **Deswal**: Member/Immediate Past Chair, Clinical Heart Failure and Transplantation Committee, Council of Clinical Cardiology, American Heart Association
37. **Deswal**: Member, National Get with the Guidelines Steering Committee, American Heart Association
38. **Deswal**: Member, Heart Failure Working Group, Get with the Guidelines, American
39. **Deswal:** Member, Guideline and Statements Committee, Heart Failure Society of America
40. **Fedson:** Member, Question Writing Committee, Advanced Heart Failure and Cardiac Transplant, American Board of Internal Medicine
41. **Fedson:** Member, Ethics Committee, Heart Failure Society of America
42. **Fedson:** Member, Guideline and Statements Committee, Heart Failure Society of America
43. **Hamzeh:** Member, ABIM Governance: Cardiovascular Disease Item-Writing Task Force
44. **Jneid:** Chair-elect, ACCF/AHA Task Force on Clinical Data Standards
45. **Jneid:** Member, ACCF/AHA Task Force on Performance Metrics
46. **Jneid:** Member, ACCF NCDR Action Registry Research & Publications Committee
47. **Jneid:** Member, Steering Committee, Fellows in Training, American Heart Association
48. **Jneid:** Member, International Committee, American Heart Association
49. **Jneid:** Member, Organizing Committee, Scientific Sessions, American Heart Association
50. **Jneid:** Writing Committee Member, ACC/AHA Chest Pain Guidelines
51. **Jneid:** Co-chair, AHA Scientific Statement on Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA)
52. **Levine:** Chair, ACC/AHA Task Force on Clinical Practice Guidelines
53. **Nair:** Member, Heart Failure and Transplantation Committee, Council on Clinical Cardiology, American Heart Association
54. **Nair:** Member, National Standards Committee for Heart Failure Care, Catholic Health Initiatives
55. **Plana:** Co-chair, Technology Incubator Task Force, American Society of Echocardiography
56. **Plana:** Member, Standards and Guidelines Committee, American Society of Echocardiography
57. **Plana:** Member, Scientific Sessions Task Force, American Society of Echocardiography
58. **Plana:** Member, Cardiac Imaging and Intervention Committee, American Heart Association
59. **Plana:** Member, Board of Directors, American Heart Association—Houston Chapter
60. **Plana:** Chair, Cardiac Imaging Subcommittee, Catholic Health Initiatives
61. **Shah:** Editorial Team Lead, Clinical Topic Collection, Heart Failure and Transplant Council, American College of Cardiology, ACC.org
62. **Shah:** Member, Heart Failure Sessions Planning Committee, 67th Scientific Sessions, American College of Cardiology
63. **Stainback:** Director, Board of Directors, American Society of Echocardiography
64. **Stainback:** Immediate Past Board Chair, Intersocietal Accreditation Commission
65. **Stainback:** President, Greater Houston Echo-Vascular Society
66. **Virani:** Chair, Leadership Council and Council for the Prevention of Cardiovascular Disease, American College of Cardiology
67. **Virani:** Chair, Research and Publications Committee, PINNACLE Registry, National Cardiovascular Data Registry, American College of Cardiology
68. **Virani:** Member, LDL: Address the Risk Think Tank, American College of Cardiology
69. **Virani:** Member, Guideline Tool Work Group, 2018 ACC/AHA Cholesterol Guideline, American College of Cardiology
70. **Virani:** Member, Research to Practice (R2P) Initiative Work Group, National Cardiovascular Data Registry, American College of Cardiology
71. **Virani:** Topic Coordinator (Prevention), Annual Scientific Session Program Committee, American College of Cardiology
72. **Virani:** Chair, Heart Disease and Stroke Statistics Committee, American Heart Association
Association

73. **Virani:** Member, EPI Leadership Committee, Council on Epidemiology and Prevention, American Heart Association

74. **Virani:** Board of Directors, American Society of Preventive Cardiology

75. **Wehrens:** Chair, Young Investigator Award competition, American Society of Clinical Investigation

76. **Wehrens:** Chair, Research Committee, Heart Rhythm Society

D. Editorial board memberships and editorial positions

1. **Ballantyne:** Editorial Director, lipidsonline.org
2. **Ballantyne:** Editorial Board, *Circulation*
3. **Ballantyne:** Editorial Board, *Clinical and Translational Science*
4. **Ballantyne:** Editorial Board, *Current Cardiology Reviews*
5. **Ballantyne:** Editorial Board, *Future Lipidology*
6. **Birnbaum:** Associate Editor, *Cardiovascular Drugs and Therapy*
7. **Birnbaum:** Special Section Editor, "Clinical Trials," *Journal of Electrocardiology*
8. **Bozkurt:** Editorial Advisory Board, *American Family Physician Journal*
9. **Bozkurt:** Senior Associate Editor, *Circulation*
10. **Bozkurt:** Associate Editor, *Circulation Heart Failure*
11. **Bozkurt:** Editorial Board, *CurrentMD*
12. **Bozkurt:** Editorial Board, *Journal of American College of Cardiology*
13. **Bozkurt:** Section Editor, "Heart Failure," *Journal of American College of Cardiology*
14. **Denktas:** Editorial Board, *Anatolian Cardiology Journal*
15. **Denktas:** Editorial Board, *Marmara University Journal*
16. **Deswal:** Guest Editor, *Circulation Heart Failure*
17. **Deswal:** Consultant, *Journal of American College of Cardiology*
18. **Deswal:** Editorial Board, *Journal of Cardiac Failure*
19. **Diez:** Editorial Board, *Texas Heart Institute Journal*
20. **Jneid:** Senior Associate Editor, *Journal of the American Heart Association*
21. **Jneid:** Editorial Board, *American Journal of Cardiology*
22. **Jneid:** Editorial Board, *Cardiovascular System*
23. **Jneid:** Editorial Board, *Journal of Geriatric Cardiology*
24. **Jneid:** Editorial Board, *Journal of the American College of Cardiology*
25. **Virani:** Associate Editor, Innovations, ACC.org
26. **Virani:** Editorial Team Member and Chair for Digital Strategy, Cardiovascular Prevention Section, ACC.org (educational web portal for the American College of Cardiology)
27. **Virani:** Advisory Board, *Advances in Therapy*
28. **Virani:** Guest Editor, *Circulation*
29. **Virani:** Editorial Board, *Circulation*
30. **Virani:** Section Editor, "Coronary Heart Disease," *Current Atherosclerosis Reports*
31. **Virani:** Associate Editor, *Journal of Clinical Lipidology* (Section specialty: Cardiovascular Outcomes and Guidelines)
32. **Virani:** Associate Editor, *Global Heart* (Official Journal of the World Heart Federation)
33. **Wehrens:** Editorial Board, *Acta Pharmacologica Sinica*
34. **Wehrens:** Editorial Board, *Circulation Research*
35. **Wehrens:** Editorial Board, *Heart Rhythm*
36. **Wehrens:** Editorial Board, *JACC Basic and Translational Research*
37. **Wehrens:** Editorial Board, *Journal of Molecular and Cellular Cardiology*


E. Other significant accomplishments

1. **Civitello**: Invited lecture, "Mechanical Circulatory Support to Manage Heart Failure," Cardio Academic—in collaboration with American College of Cardiology and European Society of Cardiology, Mexico City, Mexico

2. **Civitello**: Invited lecture, "Diagnosis of Device Thrombosis," AATS—Mechanical Circulatory Support Symposium, Houston, TX

3. **Civitello**: Invited lecture, "Timing the Transition from Short to Long Term Mechanical Circulatory Support to Transplant," AATS—Mechanical Circulatory Support Symposium, Houston, TX

4. **Civitello**: Invited lecture, "Update in Advanced Heart Failure Management," Internal Medicine Grand Rounds Conference, Houston, TX

5. **Civitello**: Invited lecture, "Utility of Counterpulsation in AMI in the Current Era," 1st Annual Houston Shock Symposium, Houston, TX

6. **Civitello**: Invited lecture, "Latest Advances in Treating Heart Failure Medically," 17th Update in Cardiovascular Advancements, Houston, TX

7. **Deswal**: Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology

8. **Deswal**: Abstract reviewer, 2018 Annual Scientific Sessions, American Heart Association

9. **Deswal**: Abstract reviewer, 2018 Annual Scientific Sessions, Heart Failure Society of America

10. **Deswal**: Presentation, "Foundations of HFpEF," national webinar, Get with the Guidelines—Heart Failure

11. **Deswal**: Faculty, Study Session for Maintenance of Certification (MOC): ABIM 2017-2018 Update in Cardiovascular Disease, Annual Scientific Sessions, American College of Cardiology, Orlando, FL

12. **Deswal**: Presentation, "Challenging Cases in Diabetes Management in Heart Failure," Annual Scientific Sessions, American College of Cardiology, Orlando, FL

13. **Deswal**: Co-Chair for session "Heart Failure with Preserved Ejection Fraction: Where Do We Go from Here?," Annual Scientific Sessions, American College of Cardiology, Orlando, FL


15. **Deswal**: Poster Professor for session "A Focus on Heart Failure Hospitalization," Annual Scientific Sessions, American Heart Association, Anaheim, CA

16. **Deswal**: Co-Chair for Session, "Pulmonary Comorbidities of HF: COPD and Sleep Apnea," Annual Scientific Sessions, Heart Failure Society of America, Dallas, TX


18. **Diez**: Invited lecture, "Combined TAVR and supravalvular therapy," Latest Advances in Treatment of Structural Heart Disease, ISEVS 2018, Houston, TX

19. **Diez**: Invited lecture, "TAVR in Special Scenarios: CHF and Pulmonary HTN," San Francisco University, Quito, Ecuador

20. **Diez**: Invited lecture, "TAVR: Expanding Clinical Indications," Cardio Academic in collaboration with American College of Cardiology and European Society of Cardiology, Mexico City, Mexico DF, Mexico

21. **Diez**: Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology
22. **Diez**: Abstract reviewer, 2018 Annual Scientific Sessions, Transcatheter Therapies – TCT
24. **Fedson**: Presentation, "New Models of Palliative Care in Heart Failure," 2018 Annual Scientific Sessions, American College of Cardiology, Orlando, FL
26. **Fedson**: Co-Chair for Session, "Reading the Tea Leaves: Prediction in Heart Failure," 2018 Scientific Sessions, International Society of Heart and Lung Transplant, Nice
27. **Fedson**: Co-Chair, "An Amalgamation of Support in Heart Failure," International Society of Heart and Lung Transplantation, San Diego, CA
28. **Fedson**: Co-Chair, Comorbidities of HFpEF, Heart Failure Society of America, Dallas TX
29. **Hamzeh**: Invited presentations, 9th Annual ECHO Boot Camp
30. **Hamzeh**: Primary investigator, Ben Taub General Hospital, ISCHEMIA Trial
31. **Hamzeh**: Primary investigator, Ben Taub General Hospital, CARMELINA Trial
32. **Hamzeh**: Primary investigator, Ben Taub General Hospital, STRENGTH Trial
33. **Hamzeh**: Primary investigator, Ben Taub General Hospital, PROMINENT Trial
34. **Hamzeh**: Mentor for fellow Dr. Mostafa El-Refai on QI project Improving Anticoagulation in Patients with Atrial Fibrillation/Flutter Received Health Care Innovation Seed grant from Department of Internal Medicine
35. **Jneid**: Member, Emerging Faculty, American College of Cardiology, 2017
36. **Jneid**: Abstract reviewer, 2018 Annual Scientific Sessions, American Heart Association
37. **Jneid**: Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology
38. **Jneid**: Course Director, Rice University community course, "Heart Health: Prevention, Treatments, Innovations"
39. **Jneid**: Speaker/Moderator at AHA, ACC, ACC Oklahoma Chapter, C3, SCAI meetings
40. **Lakkis**: Renewal of Chest Pain/STEMI with PCI Center Accreditation by ACC 2018–2021
41. **Lakkis**: 2018 Quality Achievement Award, Gold Plus Mission Lifeline STEMI receiving Center
42. **Lakkis**: 2018 Quality Achievement Award, Gold Mission Lifeline NSTEMI
43. **Lakkis**: Presentation: "Controversies in Anticoagulation," Pri-Med Southwest Annual Conference, Houston, TX
44. **Misra**: Speaker and Session Moderator, "Chest Pain Evaluation in the Office Setting," Pri-Med Southwest Annual Conference, Houston, TX
45. **Nair**: Lecture, "Heart Failure with Preserved Ejection Fraction," Baylor St Luke’s Transplant Grand Rounds, Houston, TX
46. **Nair**: Lecture, "When Right is Not Right: Pulmonary Hypertension and Right Ventricular Support," Igor F. Palacios, MD Lectureship in Cardiology, Houston, TX
47. **Nair**: Lecture, "Class III Patients Should Undergo LVAD Implantation: Pro/Con Debate," Mechanical Circulatory Support Symposium, American Association for Thoracic Surgery, Houston, TX
48. **Nair**: Lecture, "Pulmonary Hypertension in Women: What the Clinician Needs to Know," Annual Women’s Heart and Vascular Symposium, Texas Heart Institute, Houston, TX
49. **Shah**: Faculty and Course Developer, "Concerns in the management of chronic heart
failure: staying on the path to optimal medical therapy," CME activity by American College of Cardiology in partnership with Haymarket Medical Education (http://www.mycme.com/concerns-in-the-management-of-chronic-heart-failure-staying-on-the-path-to-optimal-medical-therapy/activity/5443/)

50. Shah: Abstract reviewer, 2018 Annual Scientific Sessions, American Heart Association
51. Shah: Abstract reviewer, 2018 Annual Scientific Sessions, American College of Cardiology
52. Stainback: Course Director, 9th annual Houston Echo Board Review: Boot Camp for the 2018 Echo Board
53. Stainback: Session Speaker and Session Chair, American Society of Echocardiography Scientific Sessions, 2018
54. Virani: Invited speaker, Global Cardiovascular Disease Prevention webinars in Indonesia, Malaysia, Vietnam, and UAE
55. Wehrens: Invited lecture, Cardiovascular Research Theme symposium, UCLA, Los Angeles, CA
56. Wehrens: Invited lecture, AAV Gene Therapy Symposium, Houston, TX
57. Wehrens: Invited lectures (2), Heart Rhythm Society, Boston, MA
58. Wehrens: Invited lecture, 37th Annual Conference of the North American Section of the International Society for Heart Research, Halifax, Canada

F. Grants

1. **Ballantyne (co-PI):** Profiling Cardiovascular Events and Biomarkers in the Very Old to Improve Personalized Approaches for the Prevention of Cardiac and Vascular Disease; NIH/NHLBI (R01); annual direct costs $549,802 (09/01/2016–08/31/2020)
2. **Ballantyne (coinvestigator):** Atherosclerosis Risk in Communities (ARIC) Study–Field Centers; NIH; annual direct costs $311,673 (11/15/2016–11/14/2021)
3. **Ballantyne (coinvestigator):** Monocyte Activation and the Role of CD11c in Obesity-Linked Metabolic Syndrome; NIH/NHLBI (R01); annual direct costs $241,769 (04/01/2015–03/31/2020)
4. **Ballantyne (coinvestigator):** Diabetes and Prediabetes in Older Adults; NIH/NIDDK (R01); annual direct costs $36,371 (01/01/2016–12/31/2020)
5. **Ballantyne (coinvestigator):** miRNAs, Whole Diet, and Coronary Heart Disease; NIH/NHLBI (R56); total direct costs $12,147 (09/01/2016–08/31/2018)
6. **Ballantyne (coinvestigator):** Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: $486,957 (01/01/2014–12/31/2017)
7. **Ballantyne (PI):** The Familial Hypercholesterolemia Foundation Cascade-FH Registry; Duke University; total direct costs $20,000 (07/01/2014–06/30/2019)
8. **Ballantyne (PI):** Measurement of Galectin-3 at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs $31,500 (03/14/2014–07/31/2018)
9. **Ballantyne (PI):** hsTroponin Screening at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs $371,965 (05/12/2014–05/11/2019)
10. **Ballantyne (PI):** A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD); Akcea Therapeutics; total direct costs $172,510 (02/28/2017–02/27/2020)
11. **Ballantyne (PI):** A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase
2 Study of ISIS 678354 Administered Subcutaneously to Patients with Hypertriglyceridemia and Established Cardiovascular Disease; Akcea Therapeutics; total direct costs $206,886 (03/08/2018–03/07/2021)

12. **Ballantyne (PI):** A Multicenter, Controlled, Open-Label Extension (OLE) Study to Assess the Long-Term Safety and Efficacy of AMG-145; Amgen, Inc; total direct costs $43,965 (06/01/2013–02/08/2018)

13. **Ballantyne (PI):** GAUSS-3A—Double-Blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared with Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of an HMG-CoA Reductase Inhibitor due to Muscle Related Side Effects; Amgen, Inc; total direct costs $60,085 (02/18/2014–03/21/2018)

14. **Ballantyne (PI):** A Multicenter, Open-Label, Single-Arm, Extension Study to Assess Long-Term Safety of Evolocumab Therapy in Patients with Clinically evident Cardiovascular Disease; Amgen Inc; total direct costs $45,670 (08/17/2016–12/31/2021)

15. **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled, Multicenter Long-Term Safety and Tolerability Study of ETC 1002 in Patients with Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy; Esperion Therapeutics; total direct costs $62,963 (06/27/2016–06/29/2018)

16. **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant; Esperion Therapeutics; total direct costs $40,614 (05/17/2017–04/30/2020)

17. **Ballantyne (PI):** A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of bempedoic acid (ETC1002) 180 mg/day as add-on to ezetimibe therapy in patients with elevated LDL-C; Esperion Therapeutics; total direct costs $29,253 (06/07/2017–04/25/2018)

18. **Ballantyne (PI):** A Randomized, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed-dose Combination Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy; Esperion Therapeutics; total direct costs $21,194 (11/29/2017–11/17/2018)

19. **Ballantyne (PI):** A Multicenter Open-Label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg; Esperion Therapeutics; total direct costs $22,400 (08/07/2017–12/31/2019)


21. **Birnbaum (PI):** Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after Myocardial infarction; Novartis Pharmaceuticals; total direct costs $200,000 (01/01/2018–04/01/2021)

22. **Bozkurt (Site PI):** Genomic Response Analysis of Heart Failure Therapy in African Americans; NIH/NHLBI; $84,000 (06/01/2016–05/30/2019)

23. **Bozkurt (PI):** A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Active-Controlled 8-Week Study to Evaluate the Effect of Sacubitril and Valsartan (LCZ696) versus Enalapril on Changes in NT-proBNP and Safety and Tolerability
of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF) (PIONEER-HF); Novartis; $126,000 (06/01/2016–12/31/2018)

24. **Deswal (Site PI):** Influenza Vaccine to Effectively Stop CardioThoracic Events and Decompensated Heart Failure (INVESTED); NIH/NHLBI (U05), VA Consortium; $45,000 (02/15/2016–01/31/2021)

25. **Hamzeh (PI):** CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients with Type 2 Diabetes Mellitus at High Vascular Risk; Boehringer Ingelheim; total direct costs $32,426 (10/01/2014–04/24/2018)

26. **Hamzeh (PI):** A Long-Term Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH); Astra Zeneca; total direct costs $117,000 (05/01/2015–04/30/2020)

27. **Hamzeh (PI):** Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes; Kowa Pharmaceuticals; total direct costs $30,561 (05/01/2017–04/30/2022)

28. **Misra (PI):** A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Active-Controlled 8-Week Study to Evaluate the Effect of Sacubitril and Valsartan (LCZ696) versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF) (PIONEER-HF); Novartis; total direct costs $297,000 (07/30/2016–12/31/2018)

29. **Misra (PI):** A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril Morbidity and Mortality in High Risk Patients Following an Acute Myocardial Infarction; Novartis; total direct costs $35,000 (09/01/2017–08/31/2020)

30. **Misra (PI):** A Multicenter, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction; Amgen; total direct costs $168,362 (12/01/2017–11/30/2020)

31. **Nambi (PI):** Biomarker Guided Therapies in Stage A/B Heart Failure; VA Office of Research and Development; annual direct costs $14,189 (04/01/2014–03/31/2019)

32. **Nambi (PI):** TIMI 55/REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid-Modification): A Large Scale, Randomized, Placebo-Controlled Trial of the Clinical Effects of Anacetrapib among People with Established Vascular Disease; Brigham and Women’s Hospital; total direct costs $150,000 (11/01/2011–02/28/2019)

33. **Nazeri (PI):** VIVO™ View Into Ventricular Onset Atrial Trial; Catheter Precision, Inc.

34. **Virani (PI):** Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: $486,957 (01/01/2014–12/31/2017)

35. **Virani (PI):** Determining and Targeting Reasons for Low Statin Use to Improve Guideline-Concordant Statatin Therapy in High-Risk Patients; VA Merit Award; total direct costs: $1,097,703 (07/01/2017–06/30/2021)

36. **Zhang (PI):** A Multicenter, Randomized, Double-Blind, Parallel Group, Active-Controlled
Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) with Preserved Ejection Fraction; Novartis Pharmaceuticals; total direct costs $40,550 (09/13/2013–08/31/2021)

G. Cardiovascular Research Studies at Baylor St. Luke's Medical Center with Support from Baylor Office of Clinical Research

1. Anton, James: Genomics
2. Birnbaum, Yochai: PARADISE MI
3. Tracey, Arthur: MINT
4. Civitello, Andrew: SHIELD II
5. Civitello, Andrew: IMPELLA RP HDE
6. Civitello, Andrew: ALLOMAP
7. Civitello, Andrew: PROTECTED PCI
8. Civitello, Andrew: DTU STEMI
9. Civitello, Andrew: EMBRACE HF
10. Civitello, Andrew: INTELLECT 2
11. Civitello, Andrew: GALACTIC HF
12. Krajcer, Zvonimir: MANTA
13. Krajcer, Zvonimir: ELEVATE
14. Krajcer, Zvonimir: INSPIRATION
15. Krajcer, Zvonimir: SCAFFOLD
16. Krajcer, Zvonimir: Cross-Seal
17. Krajcer, Zvonimir: NELLIX
18. Lam, Wilson: MILESTONE Phase III
19. Mathuria, Niles: IVTCC
20. Mortazavi, Ali: EVOLVE SHORT DAPT
21. Nair, Ajith: REDUCE LAP HF
22. Nazeri, Alireza: VIVO
23. Perin, Emerson: EXCEL
24. Perin, Emerson: ABSORB
25. Plana, Juan Carlos: SUCCOUR
26. Plana, Juan Carlos: ADVANCE HeartFlow
27. Rasekh, Abdi: Coherex WAVECREST 2
28. Rasekh, Abdi: aMAZE
29. Rasekh, Abdi: Vein of Marshall
30. Seger, John: MICRA PSR
31. Seger, John: ATTAIN STABILITY
32. Seger, John: ADAPT Response
33. Sherron, Scott: GRAFTMASTER HDE
34. Silva, Guilherme: AMPLATER PAS
35. Silva, Guilherme: ACCUCINCH
36. Silva, Guilherme: PIVSD Occluder HDE
37. Silva, Guilherme: The CorCinch-PMVI Study
38. Silva, Guilherme: The CorCinch-HFrEF Study
39. Silva, Guilherme: GSO 18-01
40. Strickman, Neil: TOBA II ATK
41. Strickman, Neil: INPACT
42. Strickman, Neil: TOBA II BTK
### Cardiology Faculty—Section Chief: Christie Ballantyne

**BCM Full-Time Faculty (FTE), July 2018**

<table>
<thead>
<tr>
<th>BSLMC—Service Line Chief: Juan Carlos Plana Gomez</th>
<th>Ben Taub</th>
<th>VA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arya, Basant (1.0)</strong></td>
<td>Strickman, Neil (1.0)</td>
<td>Lakkis, Nasser (0.85)</td>
</tr>
<tr>
<td>Afshar, Hamid (0.2)</td>
<td>Diez, Jose (1.0)</td>
<td>Delossantos, Olivia, NP (1.0)</td>
</tr>
<tr>
<td>Alam, Mahboob (1.0)</td>
<td>Heinle, Shelia (0.6)</td>
<td>Hamzeh, Ihab (0.4)</td>
</tr>
<tr>
<td>Birnbaum, Yochai (1.0)</td>
<td>Mathur, Virendra (0.6)</td>
<td>Medrano, Vanessa (1.0)</td>
</tr>
<tr>
<td>Denktas, Ali (.15)</td>
<td>Mihalick, Michael (1.0)</td>
<td>Misra, Arunima (1.0)</td>
</tr>
<tr>
<td>Farmer, John (1.0)</td>
<td>Molina Razavi, Joanna (1.0)</td>
<td>Pritchett, Allison (0.2)</td>
</tr>
<tr>
<td>Hamzeh, Ihab (.60)</td>
<td>Navarjio, Joseph (1.0)</td>
<td>Tabbaa, Rashed (1.0)</td>
</tr>
<tr>
<td>Koneru, Srikanth (1.0)</td>
<td>Rasekh, Abdi (1.0)</td>
<td>Zhang, Lily (1.0)</td>
</tr>
<tr>
<td>Nazeri, Alireza (1.0)</td>
<td>Razavi, Mehdi (1.0)</td>
<td>Kayani, Waleed (1.0)</td>
</tr>
<tr>
<td>Plana Gomez, Juan (1.0)</td>
<td>Saeed, Mohammad (1.0)</td>
<td>Giorgerdize, Irakli (1.0)</td>
</tr>
<tr>
<td>Loveless, Jennifer, NP (1.0)</td>
<td>Stainback, Raymond (1.0)</td>
<td>Jneid, Hani (1.0)</td>
</tr>
<tr>
<td>Griffin, Florencia, PA (1.0)</td>
<td></td>
<td>Denktas, Ali (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Afshar, Hamid (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Virani, Salim (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Schurmann, Paul (0.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shah, Tina (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Levine, Glenn (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kar, Biswajit (0.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Khalid, Umar (1.0)</td>
</tr>
</tbody>
</table>

---

**Woodlands North Houston Heart Center**

<table>
<thead>
<tr>
<th>Aquino, Vincent</th>
<th>Nemeth, Margit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lachterman, Bruce</td>
<td>Kantis, George</td>
</tr>
<tr>
<td>Lavergne, Christopher</td>
<td>Vaidya, Kedar</td>
</tr>
<tr>
<td>Peabody, Brenda</td>
<td>Nguyen, Christopher</td>
</tr>
<tr>
<td>De La Guardia, Bernardo</td>
<td>Greenberg, Scott</td>
</tr>
<tr>
<td>Alexander, Chacko</td>
<td>Brown, Jessica</td>
</tr>
</tbody>
</table>
Cardiology Fellowship Program Leadership: July 2019

BCM General Cardiology: Salim Virani, Program Director
Tina Shah, Associate Program Director, Houston VAMC
Ihab Hamzeh, Associate Program Director, Ben Taub
Mahboob Alam, Associate Program Director, BSLMC

BCM Interventional: Hani Jneid, Program Director

BCM/THI EP: Mohammad Saeed, Program Director

BCM/THI Advanced Heart Failure: Andrew Civitello, Program Director

THI Baylor GME General Cardiology: Stephanie Coulter, Program Director
George Younis, Associate Program Director

THI Interventional: David Fish, Program Director

Cardiology Fellowship Trainees:

<table>
<thead>
<tr>
<th>FY19</th>
<th># of fellows</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCM Cardiology Program</td>
<td>18</td>
</tr>
<tr>
<td>BCM Interventional Cardiology</td>
<td>3</td>
</tr>
<tr>
<td>BCM/THI Combined EP</td>
<td>4</td>
</tr>
<tr>
<td>BCM/THI Heart Failure</td>
<td>1</td>
</tr>
<tr>
<td>THI Cardiology</td>
<td>18</td>
</tr>
<tr>
<td>THI Interventional Cardiology</td>
<td>5</td>
</tr>
<tr>
<td><strong>TOTAL:</strong></td>
<td><strong>49</strong></td>
</tr>
</tbody>
</table>